(CNCR) Loncar Cancer Immunotherapy - Ratings and Ratios
Exchange: NASDAQ • Country: USA • Currency: USD • Type: Etf • ISIN: US26922A8264 • Health
CNCR: Biotechnology, Pharmaceuticals, Health, Stocks, ADRs, Cancer, Immunotherapy
The index was established in 2023 by Range Fund Holdings and tracks the performance of a portfolio of U.S. exchange-listed pharmaceutical or biotechnology stocks or American Depositary Receipts ('ADRs') with a market capitalization of more than $250 million. The advisor attempts to invest all, or substantially all, of its assets in the component securities that make up the index. Under normal circumstances, at least 80% of the fund's total assets will be invested in the component securities of the index. ‣ Company URL: http://www.LoncarFunds.com ‣ Domicile: United States
Additional Sources for CNCR ETF
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
CNCR ETF Overview
| Market Cap in USD | 10m |
| Category | Health |
| TER | 0.79% |
| IPO / Inception | 2015-10-13 |
CNCR ETF Ratings
| Growth 5y | -57.3% |
| Fundamental | - |
| Dividend | 0.30% |
| Rel. Strength Industry | -137 |
| Analysts | - |
| Fair Price Momentum | 10.67 USD |
| Fair Price DCF | - |
CNCR Dividends
| Dividend Yield 12m | 0.00% |
| Yield on Cost 5y | % |
| Annual Growth 5y | -100.00% |
| Payout Consistency | 1.0% |
CNCR Growth Ratios
| Growth Correlation 3m | -89.5% |
| Growth Correlation 12m | -54.8% |
| Growth Correlation 5y | -75.2% |
| CAGR 5y | -9.48% |
| CAGR/Mean DD 5y | -0.25 |
| Sharpe Ratio 12m | -0.27 |
| Alpha | -35.57 |
| Beta | 0.91 |
| Volatility | 42.94% |
| Current Volume | 2.4k |
| Average Volume 20d | 3.7k |
What is the price of CNCR stocks?
As of January 23, 2025, the stock is trading at USD 12.23 with a total of 2,352 shares traded.
Over the past week, the price has changed by +4.71%, over one month by -0.73%, over three months by -19.65% and over the past year by -10.01%.
As of January 23, 2025, the stock is trading at USD 12.23 with a total of 2,352 shares traded.
Over the past week, the price has changed by +4.71%, over one month by -0.73%, over three months by -19.65% and over the past year by -10.01%.
Is Loncar Cancer Immunotherapy a good stock to buy?
No, based on ValueRay Analyses, Loncar Cancer Immunotherapy (NASDAQ:CNCR) is currently (January 2025) a stock to sell. It has a ValueRay Growth Rating of -57.25 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CNCR as of January 2025 is 10.67. This means that CNCR is currently overvalued and has a potential downside of -12.76%.
No, based on ValueRay Analyses, Loncar Cancer Immunotherapy (NASDAQ:CNCR) is currently (January 2025) a stock to sell. It has a ValueRay Growth Rating of -57.25 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CNCR as of January 2025 is 10.67. This means that CNCR is currently overvalued and has a potential downside of -12.76%.
Is CNCR a buy, sell or hold?
Loncar Cancer Immunotherapy has no consensus analysts rating.
Loncar Cancer Immunotherapy has no consensus analysts rating.
What are the forecast for CNCR stock price target?
According to ValueRays Forecast Model, CNCR Loncar Cancer Immunotherapy will be worth about 11.8 in January 2026. The stock is currently trading at 12.23. This means that the stock has a potential downside of -3.27%.
According to ValueRays Forecast Model, CNCR Loncar Cancer Immunotherapy will be worth about 11.8 in January 2026. The stock is currently trading at 12.23. This means that the stock has a potential downside of -3.27%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 11.8 | -3.3% |